{
    "Trade/Device Name(s)": [
        "Thermo Scientific CEDIA Amphetamine OFT Assay",
        "CEDIA Amphetamine OFT Assay",
        "CEDIA\u00ae Amphetamine OFT Assay"
    ],
    "Submitter Information": "Thermo Fisher Scientific, Clinical Diagnostic Division",
    "510(k) Number": "K101745",
    "Predicate Device Reference 510(k) Number(s)": [
        "K051579"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ"
    ],
    "Summary Letter Date": "March 10, 2011",
    "Summary Letter Received Date": "March 14, 2011",
    "Submission Date": "February 14, 2011",
    "Regulation Number(s)": [
        "21CFR862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine"
    ],
    "Specimen Type(s)": [
        "Oral Fluid"
    ],
    "Specimen Container(s)": [
        "Oral-Eze Saliva Collection System"
    ],
    "Instrument(s)/Platform(s)": [
        "MGC 240"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Recombinant DNA technology"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Thermo Scientific CEDIA Amphetamine OFT Assay for qualitative detection of amphetamine in oral fluid using homogeneous enzyme immunoassay.",
    "Indications for Use Summary": "For qualitative determination of amphetamine in human oral fluid at 150 ng/mL cutoff, collected exclusively with Oral-Eze Saliva Collection System, for clinical laboratory use only; provides preliminary results requiring confirmation by GC/MS or LC-MS/MS.",
    "fda_folder": "Toxicology"
}